Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Documentation of Nursing Diagnosis01:10

Documentation of Nursing Diagnosis

1.8K
The nurse documents nursing diagnoses and enters them into the patient record. The identified patient's nursing diagnosis is either written out with a plan of care or entered into the electronic health record.
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
1.8K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
Detection of Gross Error: The Q Test01:00

Detection of Gross Error: The Q Test

7.1K
When one or more data points appear far from the rest of the data, there is a need to determine whether they are outliers and whether they should be eliminated from the data set to ensure an accurate representation of the measured value. In many cases, outliers arise from gross errors (or human errors) and do not accurately reflect the underlying phenomenon. In some cases, however, these apparent outliers reflect true phenomenological differences. In these cases, we can use statistical methods...
7.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.4K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.4K
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

2.1K
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
2.1K
Urine Studies I: Urinalysis01:29

Urine Studies I: Urinalysis

2.6K
Urinalysis is a widely used diagnostic test that analyzes urine's physical, chemical, and microscopic characteristics. Healthcare providers use it to detect and monitor various health conditions, including renal disease, urinary tract infections (UTIs), diabetes, and metabolic or systemic disorders.Components of UrinalysisUrinalysis consists of three primary components: physical, chemical, and microscopic examination. Each provides unique insights into the urine sample and, by extension, the...
2.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration.

Cancer cell·2026
Same author

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Exploiting immunogenic cell death to promote antitumor immunity.

Trends in immunology·2026
Same author

CLIM-TIME links genetic cancer drivers to immune landscapes.

Cell·2026
Same author

PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer.

Journal of experimental & clinical cancer research : CR·2026
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
関連記事をすべて見る

関連する実験動画

Updated: May 1, 2026

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
08:05

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting

Published on: December 12, 2011

30.6K

それは診断だ,愚かな馬鹿.

René Bernards1

  • 1Division of Molecular Carcinogenesis, Center for Biomedical Genetics and Cancer Genomics Center, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. r.bernards@nki.nl

Cell
|April 8, 2010
PubMed
まとめ
この要約は機械生成です。

分子診断の開発は,高価な標的がん治療から恩恵を受ける患者を特定し,治療費の増加に対処するために不可欠です. この議論では,薬剤反応の効果的なバイオマーカーを作成する際の課題と可能性について考察します.

さらに関連する動画

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment
05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

3.8K
Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules
10:26

Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules

Published on: May 19, 2023

2.9K

関連する実験動画

Last Updated: May 1, 2026

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
08:05

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting

Published on: December 12, 2011

30.6K
Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment
05:58

Digital Handwriting Analysis of Characters in Chinese Patients with Mild Cognitive Impairment

Published on: March 11, 2021

3.8K
Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules
10:26

Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules

Published on: May 19, 2023

2.9K

科学分野:

  • 腫瘍学 腫瘍学
  • 分子診断は分子診断です.
  • バイオマーカー開発

背景:

  • 癌治療費の上昇により,費用対効果の高い戦略が求められています.
  • ターゲティングセラピーは,パーソナライズされた治療を提供しますが,患者の選択が必要です.
  • 分子診断は,標的治療への応答者を特定することができます.

研究 の 目的:

  • 標的がん治療に対する反応を予測するための分子診断の開発について議論する.
  • 薬物反応バイオマーカーの作成における機会と障害を探求する.

主な方法:

  • 文献レビューと,分子診断における現在の動向の分析.
  • バイオマーカーの発見と検証プロセスの議論.
  • 臨床実施における課題の検討.

主要な成果:

  • 薬物反応バイオマーカーは,腫瘍学におけるパーソナライズド医療に不可欠です.
  • 新しい診断ツールの開発には大きな機会があります.
  • 障害には,バイオマーカーの検証,規制上のハードル,費用対効果などがあります.

結論:

  • 分子診断は,標的がん治療の有効性とコストを最適化するための鍵です.
  • 開発の障害を克服するために,さらなる研究と協力が必要です.
  • バイオマーカーの開発が成功すれば,患者の治療成果が改善され,医療費が削減されます.